Your browser doesn't support javascript.
loading
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
Harbeck, Nadia; Saupe, Steffen; Jäger, Elke; Schmidt, Marcus; Kreienberg, Rolf; Müller, Lothar; Otremba, Burkhard Joerg; Waldenmaier, Dirk; Dorn, Julia; Warm, Mathias; Scholz, Michael; Untch, Michael; de Wit, Maike; Barinoff, Jana; Lück, Hans-Joachim; Harter, Philipp; Augustin, Doris; Harnett, Paul; Beckmann, Matthias W; Al-Batran, Salah-Eddin.
Afiliación
  • Harbeck N; Breast Center, Department of Obstetrics and Gynecology and CCC of LMU, University of Munich, Munich, Germany. nadia.harbeck@med.uni-muenchen.de.
  • Saupe S; Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany.
  • Jäger E; Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany.
  • Schmidt M; Department of Obstetrics and Gynecology, Johannes Gutenberg University, Mainz, Germany.
  • Kreienberg R; Universitätsfrauenklinik, Ulm, Germany.
  • Müller L; Onkologische Schwerpunktpraxis, Leer, Germany.
  • Otremba BJ; Onkologische Praxis Oldenburg, Oldenburg, Germany.
  • Waldenmaier D; MSD Sharp & Dohme, Haar, Germany.
  • Dorn J; Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany.
  • Warm M; Brustzentrum, Krankenhaus Köln-Holweide, Cologne, Germany.
  • Scholz M; Trium Analysis Online GmbH, Munich, Germany.
  • Untch M; Helios Klinikum Berlin-Buch, Berlin, Germany.
  • de Wit M; Vivantes Klinikum Neukoelln, Berlin, Germany.
  • Barinoff J; Dr.-Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany.
  • Lück HJ; Dr.-Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany.
  • Harter P; Kliniken Essen-Mitte, Essen, Germany.
  • Augustin D; Klinikum des Landkreises Deggendorf, Deggendorf, Germany.
  • Harnett P; Crown Princess Mary Cancer Centre Westmead, Sydney, Australia.
  • Beckmann MW; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Erlangen, Germany.
  • Al-Batran SE; Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany.
Breast Cancer Res Treat ; 161(1): 63-72, 2017 01.
Article en En | MEDLINE | ID: mdl-27798749
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Doxorrubicina / Capecitabina / Antimetabolitos Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Año: 2017 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Doxorrubicina / Capecitabina / Antimetabolitos Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Año: 2017 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Países Bajos